Floatz logo

Immunoglobulin G1 [de-C-terminal-lysine], anti-(human epidermal growth factor receptor) (human-Mus musculus clone BCA101 ?1-chain), disulfide with human-Mus musculus clone BCA101 ?-chain fusion protein with peptide linker (GGGGS)3 fusion protein with 23-159-transforming growth factor ? receptor TGFBR2 (human), dimer

Colorectal Cancer

Bicara Therapeuticsmonoclonal_antibodyPhase 1Active
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
59/ 100

Competitive context

839 Active assets in the Colorectal Cancer cohort.

Asset / SponsorPhaseRating
Desflurane
Peter MacCallum Cancer Centre, Australia
Phase 4BBB
MARBLE DUST
James Varani
Phase 2/3BB
FLUOROURACILUM
Washington University School of Medicine
Phase 4BB
PANITUMUMAB
M.D. Anderson Cancer Center
Phase 3BB
Cetuximab
Shanghai Henlius Biotech
Phase 4BB

View all 50 →

Same molecule, other indications

Immunoglobulin G1 [de-C-terminal-lysine], anti-(human epidermal growth factor receptor) (human-Mus musculus clone BCA101 ?1-chain), disulfide with human-Mus musculus clone BCA101 ?-chain fusion protein with peptide linker (GGGGS)3 fusion protein with 23-159-transforming growth factor ? receptor TGFBR2 (human), dimer is also rated in:

EGFR AmplificationDormant
CC
Indicative ·
43 / 100
View asset →
anal canal squamous cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
squamous cell lung carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →